Who are Gynoclin V's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cleocin, Clindamycin Topical Gel 1%, Topical Clindamycin, Clindamycin Gel (clindamycin ), Dalacin C, CLDM 1% gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gynoclin-v.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Gynoclin V — Competitive Intelligence Brief

Gynoclin V (Gynoclin V) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Infectious Disease / Gynecology.

phase 3 Lincosamide antibiotic Bacterial ribosome (50S subunit) Infectious Disease / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Gynoclin V (Gynoclin V) — Janssen-Cilag, S.A.. Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gynoclin V TARGET	Gynoclin V	Janssen-Cilag, S.A.	phase 3	Lincosamide antibiotic	Bacterial ribosome (50S subunit)
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	marketed	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Clindamycin Topical Gel 1%	Clindamycin Topical Gel 1%	Jinnah Postgraduate Medical Centre	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Topical Clindamycin	Topical Clindamycin	University of Toronto	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Clindamycin Gel (clindamycin )	Clindamycin Gel (clindamycin )	Stiefel, a GSK Company	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Dalacin C	Dalacin C	Oral and Maxillofacial Surgery Clinic, Poland	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

GlaxoSmithKline · 2 drugs in this class
Balmoral Medical company · 1 drug in this class
Generic (originally Upjohn/Pfizer) · 1 drug in this class
Hospital General Universitario Elche · 1 drug in this class
Janssen-Cilag, S.A. · 1 drug in this class
Jinnah Postgraduate Medical Centre · 1 drug in this class
Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
Stiefel, a GSK Company · 1 drug in this class
Actavis Inc. · 1 drug in this class
University of Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gynoclin V — Competitive Intelligence Brief. https://druglandscape.com/ci/gynoclin-v. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab